Abstract

Calcium supplementation has been considered the gold standard therapy for osteoporosis in the general population. It is given in both the placebo and treatment groups of trials evaluating antifracture efficacy of new therapies. Similarly, calcium-based phosphate binders have been considered the gold standard comparator for all new phosphate binders. However, large randomized trials demonstrate conflicting data on the antifracture efficacy of calcium supplementation, particularly in high doses, in patients with osteoporosis without CKD. In addition, recent data suggest an increased risk for cardiovascular events. These new studies raise safety concerns for the general approach with calcium supplementation and binders. This review describes recent data on the adverse effects of calcium supplementation for osteoporosis and how these new data should affect the strategy for phosphate binder use in CKD.

Links

Publisher Full Text

Authors

Jamal SA, Moe SM

Institution

University of Toronto, Toronto, Ontario, Canada.

Source

Clinical journal of the American Society of Nephrology : CJASN 7:11 2012 Nov pg 1877-83

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22837272